Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs

Drug Safety

Volumn 38, Issue 11, 2015, Pages 1059-1074

  Petrovsky, Nikolai ^a,b  

^a FLINDERS UNIVERSITY   (Australia)

^b VAXINE PTY LTD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM DERIVATIVE; ENTEROTOXIN; GLYCOLIPID; IMMUNOLOGICAL ADJUVANT; PHOSPHORYL LIPID A; POLYSACCHARIDE; SAPONIN; TOLL LIKE RECEPTOR AGONIST; VACCINE;

ALLERGY; ALZHEIMER DISEASE; ANAPHYLAXIS; ARTHRALGIA; ASTHENIA; COMPARATIVE STUDY; CONSUMER; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; EMULSION; FASCIITIS; FEVER; GRANULOMA; HEADACHE; HUMAN; IMMUNOGENICITY; INFLAMMATION; INJECTION SITE ERYTHEMA; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE STERILE ABSCESS; INJECTION SITE SWELLING; LETHARGY; LYMPHADENOPATHY; MACROPHAGIC MYOFASCIITIS; MALAISE; MUSCLE INJURY; MUSCLE WEAKNESS; MYALGIA; NARCOLEPSY; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SKIN ULCER; ANIMAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FORECASTING; STANDARDS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FORECASTING; HUMANS; VACCINES;

EID: 84945197664     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-015-0350-4     Document Type: Review

References (160)

1. Poolman JT. Shortcomings of pertussis vaccines: why we need a third generation vaccine. Expert Rev Vaccines. 2014;13(10):1159–62.
2. Li-Kim-Moy J, Booy R. The manufacturing process should remain the focus for severe febrile reactions in children administered an Australian inactivated influenza vaccine during 2010. Influenza Other Respir Viruses. 2015. doi:10.1111/irv.12337.
3. Aichinger G, Grohmann-Izay B, van der Velden MV, Fritsch S, Koska M, Portsmouth D, et al. Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults. Clin Vaccine Immunol. 2015;22(1):46–55.
4. Rockman S, Dyson A, Koernig S, Becher D, Ng M, Morelli AB, et al. Evaluation of the bioactivity of influenza vaccine strains in vitro suggests that the introduction of new strains in the 2010 Southern Hemisphere trivalent influenza vaccine is associated with adverse events. Vaccine. 2014;32(30):3861–8.
5. Petrovsky N, Heinzel S, Honda Y, Lyons AB. New-age vaccine adjuvants: friend or foe? Biopharm Int. 2007;20(8):24–33.
6. Petrovsky N. Freeing vaccine adjuvants from dangerous immunological dogma. Expert Rev Vaccines. 2008;7(1):7–10.
7. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004;82(5):488–96.
8. Ahmed SS, Schur PH, MacDonald NE, Steinman L. Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. J Autoimmun. 2014;50:1–11.
9. Vera-Lastra O, Medina G, Cruz-Dominguez Mdel P, Jara LJ, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld’s syndrome): clinical and immunological spectrum. Expert Rev Clin Immunol. 2013;9(4):361–73.
10. Gherardi RK, Authier FJ. Aluminum inclusion macrophagic myofasciitis: a recently identified condition. Immunol Allergy Clin N Am. 2003;23(4):699–712.
11. Willhite CC, Karyakina NA, Yokel RA, Yenugadhati N, Wisniewski TM, Arnold IM, et al. Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts. Crit Rev Toxicol. 2014;44(Suppl 4):1–80.
12. Leventhal JS, Berger EM, Brauer JA, Cohen DE. Hypersensitivity reactions to vaccine constituents: a case series and review of the literature. Dermatitis. 2012;23(3):102–9.
13. Powell BS, Andrianov AK, Fusco PC. Polyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytes. Clin Exp Vaccine Res. 2015;4(1):23–45.
14. Butler NR, Voyce MA, Burland WL, Hilton ML. Advantages of aluminium hydroxide adsorbed combined diphtheria, tetanus, and pertussis vaccines for the immunization of infants. Br Med J. 1969;1(645):663–6.
15. Cherin P, Gherardi RK. Emergence of a new entity, the macrophagic myofasciitis. GERMMAD Study Group of the French Association Against Myopathies. Study and Research Group on Acquired Dysimmunity-Related Muscle Disease. Rev Rhum Engl Ed. 1998;65(10):541–2.
16. World Health Organization Global Advisory Committee on Vaccine Safety. Questions and answers about macrophagic myofasciitis (MMF). World Health Organization. 2008. http://www.who.int/vaccine_safety/committee/topics/aluminium/questions/en/. Accessed 19 Aug 2015.
17. Aghazadeh-Habashi A, Kohan MH, Asghar W, Jamali F. Glucosamine dose/concentration–effect correlation in the rat with adjuvant arthritis. J Pharm Sci. 2014;103(2):760–7.
18. Marson A, Housley WJ, Hafler DA. Genetic basis of autoimmunity. J Clin Invest. 2015;125(6):2234–41.
19. Nohynek H, Jokinen J, Partinen M, Vaarala O, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One. 2012;7(3):e33536.
20. Partinen M, Saarenpaa-Heikkila O, Ilveskloski I. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS One. 2012;7(3):e33723.
21. Rigolet M, Aouizerate J, Couette M, Ragunathan-Thangarajah N, Aoun-Sebaiti M, Gherardi RK, et al. Clinical features in patients with long-lasting macrophagic myofasciitis. Front Neurol. 2014;5:230.
22. Lima H Jr, Jacobson LS, Goldberg MF, Chandran K, Diaz-Griffero F, Lisanti MP, et al. Role of lysosome rupture in controlling Nlrp3 signaling and necrotic cell death. Cell Cycle. 2013;12(12):1868–78.
23. Gupta RK. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev. 1998;32(3):155–72.
24. Goto N, Kato H, Maeyama J, Shibano M, Saito T, Yamaguchi J, et al. Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties. Vaccine. 1997;15(12–13):1364–71.
25. Pusic K, Aguilar Z, McLoughlin J, Kobuch S, Xu H, Tsang M, et al. Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine. FASEB J. 2013;27(3):1153–66.
26. Lee JY, Atochina O, King B, Taylor L, Elloso M, Scott P, et al. Beryllium, an adjuvant that promotes gamma interferon production. Infect Immun. 2000;68(7):4032–9.
27. Lin Y, Epstein DL, Liton PB. Intralysosomal iron induces lysosomal membrane permeabilization and cathepsin D-mediated cell death in trabecular meshwork cells exposed to oxidative stress. Invest Ophthalmol Vis Sci. 2010;51(12):6483–95.
28. Dinsdale D. Lysosomal involvement in beryllium phosphate toxicity. Br J Exp Pathol. 1982;63(1):103–8.
29. Hall JG. Studies on the adjuvant action of beryllium: IV. The preparation of beryllium containing macromolecules that induce immunoblast responses in vivo. Immunology. 1988;64(2):345–51.
30. Doherty PC, Turner SJ, Webby RG, Thomas PG. Influenza and the challenge for immunology. Nat Immunol. 2006;7(5):449–55.
31. Jensen-Jarolim E. Aluminium in allergies and allergen immunotherapy. World Allergy Organ J. 2015;8(1):7.
32. Aimanianda V, Haensler J, Lacroix-Desmazes S, Kaveri SV, Bayry J. Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants. Trends Pharmacol Sci. 2009;30(6):287–95.
33. Netterlid E, Hindsen M, Siemund I, Bjork J, Werner S, Jacobsson H, et al. Does allergen-specific immunotherapy induce contact allergy to aluminium? Acta Derm Venereol. 2013;93(1):50–6.
34. Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013;25(6):469–84.
35. Audibert FM, Lise LD. Adjuvants: current status, clinical perspectives and future prospects. Immunol Today. 1993;14(6):281–4.
36. Bomford R. Aluminium salts: perspectives in their use as adjuvants. In: Gregoriadis GA, Allison AC, Poste G, editors. Immunological adjuvants and vaccines. New York Plenum Press; 1989. p. 35–41.
37. Goto N, Kato H, Maeyama J, Eto K, Yoshihara S. Studies on the toxicities of aluminium hydroxide and calcium phosphate as immunological adjuvants for vaccines. Vaccine. 1993;11(9):914–8.
38. Nieuwenhuizen N, Herbert DR, Lopata AL, Brombacher F. CD4+ T cell–specific deletion of IL-4 receptor alpha prevents ovalbumin-induced anaphylaxis by an IFN-gamma-dependent mechanism. J Immunol. 2007;179(5):2758–65.
39. Xu W, Tamura T, Takatsu K. CpG ODN mediated prevention from ovalbumin-induced anaphylaxis in mouse through B cell pathway. Int Immunopharmacol. 2008;8(2):351–61.
40. White OJ, McKenna KL, Bosco A, HJvdB A, Richmond P, Holt PG. A genomics-based approach to assessment of vaccine safety and immunogenicity in children. Vaccine. 2012;30(10):1865–74.
41. De Swart RL, Kuiken T, Timmerman HH, van Amerongen G, Van Den Hoogen BG, Vos HW, et al. Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection. J Virol. 2002;76(22):11561–9.
42. Honda-Okubo Y, Barnard D, Ong CH, Peng BH, Tseng CT, Petrovsky N. Severe acute respiratory syndrome–associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. J Virol. 2015;89(6):2995–3007.
43. Openshaw PJ, Culley FJ, Olszewska W. Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine. 2001;15(20 Suppl 1):S27–31.
44. Vascellari M, Melchiotti E, Bozza MA, Mutinelli F. Fibrosarcomas at presumed sites of injection in dogs: characteristics and comparison with non-vaccination site fibrosarcomas and feline post-vaccinal fibrosarcomas. J Vet Med A Physiol Pathol Clin Med. 2003;50(6):286–91.
45. Cherin P, Gherardi RK. Macrophagic myofasciitis. Curr Rheumatol Rep. 2000;2(3):196–200.
46. Gherardi RK, Coquet M, Cherin P, Belec L, Moretto P, Dreyfus PA, et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain. 2001;124(Pt 9):1821–31.
47. Authier FJ, Cherin P, Creange A, Bonnotte B, Ferrer X, Abdelmoumni A, et al. Central nervous system disease in patients with macrophagic myofasciitis. Brain. 2001;124(Pt 5):974–83.
48. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet. 2001;29(3):301–5.
49. Bingley PJ, Hoffbrand BI. Antiphospholipid antibody syndrome: a review. J R Soc Med. 1987;80(7):445–8.
50. Zivkovic I, Petrusic V, Stojanovic M, Inic-Kanada A, Stojicevic I, Dimitrijevic L. Induction of decreased fecundity by tetanus toxoid hyper-immunization in C57BL/6 mice depends on the applied adjuvant. Innate immunity. 2012;18(2):333–42.
51. Reusche E, Seydel U. Dialysis-associated encephalopathy: light and electron microscopic morphology and topography with evidence of aluminum by laser microprobe mass analysis. Acta Neuropathol. 1993;86(3):249–58.
52. Miu AC, Benga O. Aluminum and Alzheimer’s disease: a new look. J Alzheimer’s Dis. 2006;10(2–3):179–201.
53. Kramer MF, Heath MD. Aluminium in allergen-specific subcutaneous immunotherapy—a German perspective. Vaccine. 2014;32(33):4140–8.
54. Eidi H, David MO, Crepeaux G, Henry L, Joshi V, Berger MH, et al. Fluorescent nanodiamonds as a relevant tag for the assessment of alum adjuvant particle biodisposition. BMC Med. 2015;13:144.
55. Shaw CA, Li Y, Tomljenovic L. Administration of aluminium to neonatal mice in vaccine-relevant amounts is associated with adverse long term neurological outcomes. J Inorg Biochem. 2013;128:237–44.
56. Shaw CA, Tomljenovic L. Aluminum in the central nervous system (CNS): toxicity in humans and animals, vaccine adjuvants, and autoimmunity. Immunol Res. 2013;56(2–3):304–16.
57. Shaw CA, Li D, Tomljenovic L. Are there negative CNS impacts of aluminum adjuvants used in vaccines and immunotherapy? Immunotherapy. 2014;6(10):1055–71.
58. Fanni D, Ambu R, Gerosa C, Nemolato S, Iacovidou N, Van Eyken P, et al. Aluminum exposure and toxicity in neonates: a practical guide to halt aluminum overload in the prenatal and perinatal periods. World J Pediatr. 2014;10(2):101–7.
59. World Health Organization. Global Advisory Committee on Vaccine Safety, June 2012. WHO Wkly Epidemiol Rec. 2012;87(30):277–88.
60. von Biela LM. A disclosure dilemma: what you don’t know can kill you, but so can what you do know. Food Drug Law J. 2010;65(2):317–46 (ii).
61. Lindblad EB. Aluminium adjuvants—in retrospect and prospect. Vaccine. 2004;22(27–28):3658–68.
62. Verdier F, Burnett R, Michelet-Habchi C, Moretto P, Fievet-Groyne F, Sauzeat E. Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the Cynomolgus monkey. Vaccine. 2005;23(11):1359–67.
63. van Dissel JT, Joosten SA, Hoff ST, Soonawala D, Prins C, Hokey DA, et al. A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis–specific T-cell responses in human. Vaccine. 2014;32(52):7098–107.
64. Stills HF Jr. Adjuvants and antibody production: dispelling the myths associated with Freund’s complete and other adjuvants. ILAR J. 2005;46(3):280–93.
65. Herbert WJ. The mode of action of mineral-oil emulsion adjuvants on antibody production in mice. Immunology. 1968;14(3):301–18.
66. ® ISA 720. PLoS One. 2011;6(9):e24413.
67. Vera-Lastra O, Medina G, Cruz-Dominguez Mdel P, Ramirez P, Gayosso-Rivera JA, Anduaga-Dominguez H, et al. Human adjuvant disease induced by foreign substances: a new model of ASIA (Shoenfeld’s syndrome). Lupus. 2012;21(2):128–35.
68. Whitehouse M. Oily adjuvants and autoimmunity: now time for reconsideration? Lupus. 2012;21(2):217–22.
69. Kuroda Y, Akaogi J, Nacionales DC, Wasdo SC, Szabo NJ, Reeves WH, et al. Distinctive patterns of autoimmune response induced by different types of mineral oil. Toxicol Sci. 2004;78(2):222–8.
70. Koppang EO, Bjerkas I, Haugarvoll E, Chan EK, Szabo NJ, Ono N, et al. Vaccination-induced systemic autoimmunity in farmed Atlantic salmon. J Immunol. 2008;181(7):4807–14.
71. Holm BC, Lorentzen JC, Bucht A. Adjuvant oil induces waves of arthritogenic lymph node cells prior to arthritis onset. Clin Exp Immunol. 2004;137(1):59–64.
72. Howell CD, Yoder TD. Murine experimental autoimmune hepatitis: nonspecific inflammation due to adjuvant oil. Clin Immunol Immunopathol. 1994;72(1):76–82.
73. Lorentzen JC, Klareskog L. Susceptibility of DA rats to arthritis induced with adjuvant oil or rat collagen is determined by genes both within and outside the major histocompatibility complex. Scand J Immunol. 1996;44(6):592–8.
74. Svelander L, Erlandsson Harris H, Lorentzen JC, Trollmo C, Klareskog L, Bucht A. Oligodeoxynucleotides containing CpG motifs can induce T cell–dependent arthritis in rats. Arthritis Rheum. 2004;50(1):297–304.
75. ®-adjuvanted influenza vaccines for associated cases of narcolepsy. Scand J Infect Dis. 2011;43(9):702–6.
76. Cosmi L, Liotta F, Maggi E, Romagnani S, Annunziato F. Th17 and non-classic Th1 cells in chronic inflammatory disorders: two sides of the same coin. Int Arch Allergy Immunol. 2014;164(3):171–7.
77. Sutton C, Brereton C, Keogh B, Mills KH, Lavelle EC. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med. 2006;203(7):1685–91.
78. Vitoriano-Souza J, Moreira N, Teixeira-Carvalho A, Carneiro CM, Siqueira FA, Vieira PM, et al. Cell recruitment and cytokines in skin mice sensitized with the vaccine adjuvants: saponin, incomplete Freund’s adjuvant, and monophosphoryl lipid A. PLoS One. 2012;7(7):e40745.
79. Kensil CR, Kammer R. QS-21: a water-soluble triterpene glycoside adjuvant. Expert Opin Investig Drugs. 1998;7(9):1475–82.
80. Wu JY, Gardner BH, Murphy CI, Seals JR, Kensil CR, Recchia J, et al. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. J Immunol. 1992;148(5):1519–25.
81. Stewart TJ, Drane D, Malliaros J, Elmer H, Malcolm KM, Cox JC, et al. Iscomatrix adjuvant: an adjuvant suitable for use in anticancer vaccines. Vaccine. 2004;22(27–28):3738–43.
82. Waite DC, Jacobson EW, Ennis FA, Edelman R, White B, Kammer R, et al. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine. 2001;19(28–29):3957–67.
83. Lorent JH, Quetin-Leclercq J, Mingeot-Leclercq MP. The amphiphilic nature of saponins and their effects on artificial and biological membranes and potential consequences for red blood and cancer cells. Org Biomol Chem. 2014;12(44):8803–22.
84. Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A. ISCOM, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature. 1984;308(5958):457–60.
85. Claassen I, Osterhaus A. The ISCOM structure as an immune-enhancing moiety: experience with viral systems. Res Immunol. 1992;143(5):531–41.
86. Ronnberg B, Fekadu M, Morein B. Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix. Vaccine. 1995;13(14):1375–82.
87. Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, et al. Recombinant NY-ESO-1 protein with Iscomatrix adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci. 2004;101(29):10697–702.
88. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61(1):46–54.
89. Asuni AA, Boutajangout A, Scholtzova H, Knudsen E, Li YS, Quartermain D, et al. Vaccination of Alzheimer’s model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages. Eur J Neurosci. 2006;24(9):2530–42.
90. Verstak B, Hertzog P, Mansell A. Toll-like receptor signalling and the clinical benefits that lie within. Inflamm Res. 2007;56(1):1–10.
91. Collins SE, Mossman KL. Danger, diversity and priming in innate antiviral immunity. Cytokine Growth Factor Rev. 2014;25(5):525–31.
92. Alving CR, Peachman KK, Rao M, Reed SG. Adjuvants for human vaccines. Curr Opin Immunol. 2012;24(3):310–5.
93. Tong NK, Beran J, Kee SA, Miguel JL, Sanchez C, Bayas JM, et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int. 2005;68(5):2298–303.
94. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, et al. AS04, an aluminum salt- and TLR4 agonist–based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol. 2009;183(10):6186–97.
95. Maroof A, Yorgensen YM, Li Y, Evans JT. Intranasal vaccination promotes detrimental Th17-mediated immunity against influenza infection. PLoS Pathog. 2014;10(1):e1003875.
96. Naik SR, Wala SM. Arthritis, a complex connective and synovial joint destructive autoimmune disease: animal models of arthritis with varied etiopathology and their significance. J Postgrad Med. 2014;60(3):309–17.
97. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol. 2000;164(3):1617–24.
98. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci. 1996;93(7):2879–83.
99. Krug A, Rothenfusser S, Selinger S, Bock C, Kerkmann M, Battiany J, et al. CpG-A oligonucleotides induce a monocyte-derived dendritic cell–like phenotype that preferentially activates CD8 T cells. J Immunol. 2003;170(7):3468–77.
100. Klinman DM, Barnhart KM, Conover J. CpG motifs as immune adjuvants. Vaccine. 1999;17(1):19–25.
101. Krieg AM, Efler SM, Wittpoth M, Al Adhami MJ, Davis HL. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother (1997). 2004;27(6):460–71.
102. Jegerlehner A, Maurer P, Bessa J, Hinton HJ, Kopf M, Bachmann MF. TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol. 2007;178(4):2415–20.
103. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discovery. 2006;5(6):471–84.
104. Agrawal S, Temsamani J, Tang JY. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci. 1991;88(17):7595–9.
105. Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, Akira S, et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med. 2004;10(2):187–92.
106. Scheiermann J, Klinman DM. Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer. Vaccine. 2014;32(48):6377–89.
107. Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM, et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol. 2004;24(6):693–701.
108. Halperin SA, Dobson S, McNeil S, Langley JM, Smith B, McCall-Sani R, et al. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine. 2006;24(1):20–6.
109. Halperin SA, Ward B, Cooper C, Predy G, Diaz-Mitoma F, Dionne M, et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age. Vaccine. 2012;30(15):2556–63.
110. Sablan BP, Kim DJ, Barzaga NG, Chow WC, Cho M, Ahn SH, et al. Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. Vaccine. 2012;30(16):2689–96.
111. Heyward WL, Kyle M, Blumenau J, Davis M, Reisinger K, Kabongo ML, et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age. Vaccine. 2013;31(46):5300–5.
112. US Food and Drug Administration. 2012 meeting materials, Vaccines and Related Biological Products Advisory Committee. US Food and Drug Administration. 2012. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/ucm288695.htm. Accessed 23 Sept 2015.
113. Mizel SB, Bates JT. Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol. 2010;185(10):5677–82.
114. Treanor JJ, Taylor DN, Tussey L, Hay C, Nolan C, Fitzgerald T, et al. Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine. 2010;28(52):8268–74.
115. Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine. 2011;29(32):5145–52.
116. Larena M, Holmgren J, Lebens M, Terrinoni M, Lundgren A. Cholera toxin, and the related nontoxic adjuvants mmCT and dmLT, promote human Th17 responses via cyclic AMP–protein kinase A and inflammasome-dependent IL-1 signaling. J Immunol. 2015;194(8):3829–39.
117. Holmgren J, Lycke N, Czerkinsky C. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine. 1993;11(12):1179–84.
118. Freytag LC, Clements JD. Mucosal adjuvants. Vaccine. 2005;23(15):1804–13.
119. Liang S, Hajishengallis G. Heat-labile enterotoxins as adjuvants or anti-inflammatory agents. Immunol Invest. 2010;39(4–5):449–67.
120. Lewis DJ, Huo Z, Barnett S, Kromann I, Giemza R, Galiza E, et al. Transient facial nerve paralysis (Bell’s palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One. 2009;4(9):e6999.
121. Petrovsky N, Cooper PD. Carbohydrate-based immune adjuvants. Expert Rev Vaccines. 2011;10(4):523–37.
122. Cooper PD, Petrovsky N. Delta inulin: a novel, immunologically active, stable packing structure comprising beta-D-[2 → 1] poly(fructo-furanosyl) alpha-D-glucose polymers. Glycobiology. 2011;21(5):595–606.
123. Honda-Okubo Y, Saade F, Petrovsky N. Advax, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses. Vaccine. 2012;30(36):5373–81.
124. Lobigs M, Pavy M, Hall RA, Lobigs P, Cooper P, Komiya T, et al. An inactivated Vero cell–grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses. J Gen Virol. 2010;91(Pt 6):1407–17.
125. Rodriguez-Del Rio E, Marradi M, Calderon-Gonzalez R, Frande-Cabanes E, Penades S, Petrovsky N, et al. A gold glyco-nanoparticle carrying a listeriolysin O peptide and formulated with Advax delta inulin adjuvant induces robust T-cell protection against listeria infection. Vaccine. 2015;33(12):1465–73.
126. Petrovsky N, Larena M, Siddharthan V, Prow NA, Hall RA, Lobigs M, et al. An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody. J Virol. 2013;87(18):10324–33.
127. Feinen B, Petrovsky N, Verma A, Merkel TJ. Advax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvant. Clin Vaccine Immunol. 2014;21(4):580–6.
128. Honda-Okubo Y, Kolpe A, Li L, Petrovsky N. A single immunization with inactivated H1N1 influenza vaccine formulated with delta inulin adjuvant (Advax) overcomes pregnancy-associated immune suppression and enhances passive neonatal protection. Vaccine. 2014;32(36):4651–9.
129. Honda-Okubo Y, Ong CH, Petrovsky N. Advax delta inulin adjuvant overcomes immune immaturity in neonatal mice thereby allowing single-dose influenza vaccine protection. Vaccine. 2015;33(38):4892–900.
130. Mastelic Gavillet B, Eberhardt CS, Auderset F, Castellino F, Seubert A, Tregoning JS, et al. MF59 mediates its B cell adjuvanticity by promoting T follicular helper cells and thus germinal center responses in adult and early life. J Immunol. 2015;194(10):4836–45.
131. Gordon D, Kelley P, Heinzel S, Cooper P, Petrovsky N. Immunogenicity and safety of Advax, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled phase 1 study. Vaccine. 2014;32(48):6469–77.
132. Gordon DL, Sajkov D, Woodman RJ, Honda-Okubo Y, Cox MM, Heinzel S, et al. Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax polysaccharide adjuvant. Vaccine. 2012;30(36):5407–16.
133. Heddle R, Russo P, Petrovsky N, Hanna R, Smith A. Immunotherapy—2076. A controlled study of delta inulin–adjuvanted honey bee venom immunotherapy. World Allergy Organ J. 2013;6(Suppl 1):P158-P.
134. Szebeni J. Complement activation–related pseudoallergy caused by amphiphilic drug carriers: the role of lipoproteins. Curr Drug Deliv. 2005;2(4):443–9.
135. Tefit JN, Crabe S, Orlandini B, Nell H, Bendelac A, Deng S, et al. Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination. Vaccine. 2014;32(46):6138–45.
136. Takeda K, Hayakawa Y, Van Kaer L, Matsuda H, Yagita H, Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci. 2000;97(10):5498–503.
137. Sesardic D. Regulatory considerations on new adjuvants and delivery systems. Vaccine. 2006;24 Suppl 2:S2-86–7.
138. Beck FW, Whitehouse MW, Pearson CM. Improvements for consistently inducing experimental allergic encephalomyelitis (EAE) in rats: I. without using mycobacterium. II. Inoculating encephalitogen into the ear. Proc Soc Exp Biol Med. 1976;151(3):615–22.
139. Panitch H, Ciccone C. Induction of recurrent experimental allergic encephalomyelitis with myelin basic protein. Ann Neurol. 1981;9(5):433–8.
140. Barkhordarian A, Thames AD, Du AM, Jan AL, Nahcivan M, Nguyen MT, et al. Viral immune surveillance: toward a TH17/TH9 gate to the central nervous system. Bioinformation. 2015;11(1):47–54.
141. Mastelic B, Garcon N, Del Giudice G, Golding H, Gruber M, Neels P, et al. Predictive markers of safety and immunogenicity of adjuvanted vaccines. Biologicals. 2013;41(6):458–68.
142. Sun Y, Gruber M, Matsumoto M. Overview of global regulatory toxicology requirements for vaccines and adjuvants. J Pharmacol Toxicol Methods. 2012;65(2):49–57.
143. Tiwari JL, Terasaki PI. HLA-DR and disease associations. Prog Clin Biol Res. 1981;58:151–63.
144. Vaarala O, Vuorela A, Partinen M, Baumann M, Freitag TL, Meri S, et al. Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for pandemrix-associated narcolepsy risk. PLoS One. 2014;9(12):e114361.
145. Schroder K, Irvine KM, Taylor MS, Bokil NJ, Le Cao KA, Masterman KA, et al. Conservation and divergence in Toll-like receptor 4–regulated gene expression in primary human versus mouse macrophages. Proc Natl Acad Sci. 2012;109(16):E944–53.
146. Zaitseva M, Romantseva T, Blinova K, Beren J, Sirota L, Drane D, et al. Use of human MonoMac6 cells for development of in vitro assay predictive of adjuvant safety in vivo. Vaccine. 2012;30(32):4859–65.
147. Pignatti F, Jonsson B, Blumenthal G, Justice R. Assessment of benefits and risks in development of targeted therapies for cancer—the view of regulatory authorities. Mol Oncol. 2015;9(5):1034–41.
148. Thompson A, Komparic A, Smith MJ. Ethical considerations in post-market-approval monitoring and regulation of vaccines. Vaccine. 2014;32(52):7171–4.
149. Bults M, Beaujean DJ, Richardus JH, van Steenbergen JE, Voeten HA. Pandemic influenza A (H1N1) vaccination in the Netherlands: parental reasoning underlying child vaccination choices. Vaccine. 2011;29(37):6226–35.
150. Ropeik D. How society should respond to the risk of vaccine rejection. Hum Vaccines Immunother. 2013;9(8):1815–8.
151. Leask J, Braunack-Mayer A, Kerridge I. Consent and public engagement in an era of expanded childhood immunisation. J Paediatr Child Health. 2011;47(9):603–7.
152. Spadea A, Unim B, Colamesta V, Meneghini A, D’Amici AM, Giudiceandrea B, et al. Is the adjuvanted influenza vaccine more effective than the trivalent inactivated vaccine in the elderly population? Results of a case–control study. Vaccine. 2014;32(41):5290–4.
153. Begue P. Consequences of opposition to vaccination in France and Europe. How to maintain effective vaccine coverage in 2010?. Bulletin de l’Academie nationale de medecine. 2010;194(4–5):719–32 (discussion 732).
154. Butler D. Regulators face tough flu-jab choices. Nature. 2009;460(7254):446.
155. How to win trust over flu. Nature. 2009;461(7265):698.
156. Opel DJ, Marcuse EK. Rethinking vaccine policy making in an era of vaccine hesitancy: time to rebuild, not remodel? Hum Vaccines Immunother. 2013;9(12):2672–3.
157. Glanz JM, McClure DL, Magid DJ, Daley MF, France EK, Salmon DA, et al. Parental refusal of pertussis vaccination is associated with an increased risk of pertussis infection in children. Pediatrics. 2009;123(6):1446–51.
158. Buttenheim AM, Cherng ST, Asch DA. Provider dismissal policies and clustering of vaccine-hesitant families: an agent-based modeling approach. Hum Vaccines Immunother. 2013;9(8):1819–24.
159. Folb PI, Bernatowska E, Chen R, Clemens J, Dodoo AN, Ellenberg SS, et al. A global perspective on vaccine safety and public health: the Global Advisory Committee on Vaccine Safety. Am J Public Health. 2004;94(11):1926–31.
160. Elmgren L, Li X, Wilson C, Ball R, Wang J, Cichutek K, et al. A global regulatory science agenda for vaccines. Vaccine. 2013;18(31 Suppl 2):B163–75.